Table 1

Characteristics of the whole SLE cohort and of the anti-P-positive and anti-NR2-positive patients

	Whole SLE cohort (N=33)	Anti-P positive (N=6)	P value*	Anti-NR2 positive (N=14)	P value†
Age, years, mean (SD)	43.5 (14.0)	40.6 (12.2)	0.591	39.1 (14.2)	0.113
Gender, male	3 (9%)	0	0.392	0	0.119
Disease duration, months, median (IQR)	124.4 (34.7–305)	282.5 (188.5–414.1)	0.129	241.1 (81.2–332.4)	0.316
SLEDAI-2K, median (IQR)	4 (0–14)	7 (6–12.5)	0.420	6 (2–13.5)	0.394
SLICC-DI, median (IQR)	0 (0–1)	0 (0–1)	0.958	0 (0–1)	0.934
C3, mean (SD)	89.9 (20.8)	87.4 (19.9)	0.724	84.7 (20.3)	0.285
C4, mean (SD)	13.7 (6.6)	12.4 (5.2)	0.681	13.2 (6.0)	0.706
Antiphospholipid‡ antibodies	11 (33.3%)	2 (33.3%)	1	4 (26.7%)	0.618
anti-dsDNA	18 (54.5%)	5 (83.3%)	0.117	9 (60%)	0.335
Anti-Ro/SSA	16 (48.5%)	3 (50%)	0.935	8 (53.3%)	0.393
Anti-La/SSB	4 (12.1%)	0	0.315	2 (13.3%)	0.744
Anti-RNP	11 (33.3%)	3 (50%)	0.338	4 (26.7%)	0.618
anti-Sm	10 (30.3%)	2 (33.3%)	0.858	5 (33.3%)	0.561
SF-12 questionnaire, median (IQR)	35.0 (31.0–37.0)	31.5 (21.0–38.0)	0.467	32.0 (28.0–37.0)	0.486
SF-12 MCS, median (IQR)	19.0 (21.0–16.5)	16.5 (13.0–18.0)	0.159	18.0 (16.0–19.0)	0.134
SF-12 PCS, median (IQR)	14.5 (13.0–17.0)	15.0 (12.0–18.0)	0.979	16.0 (14.0–19.0)	0.167
Dose PDN, mg/daily, median (IQR)	6.4 (3.8–13.5)	10.8 (8.2)	0.640	8.8 (4.4–12.7)	0.412

Unless otherwise specified, values are absolute numbers and values in brackets are percentages.
*P values obtained comparing anti-P-positive and anti-P-negative patients.
†P values obtained comparing anti-NR2-positive and anti-NR2-negative patients.
‡Lupus anticoagulant and/or anticardiolipin IgM/IgG and/or anti-β2-glycoprotein-1 IgM/IgG.
anti-NR2, anti-N-methyl-D-aspartic acid receptor subunit 2; anti-P, anti-ribosomal P protein; dsDNA, double-stranded DNA; MCS, mental component summary; PCS, physical component summary; PDN, prednisone; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.